The history and mission of M Stem Cell Laboratories
M Stem Cell Laboratories was established in 2009 with initial funding from the University of Michigan’s Taubman Institute.
Dr. Gary D. Smith, founding director of M Stem Cell, and A. Alfred Taubman, the noted Michigan businessman and philanthropist, had been active in the statewide effort to legalize the use of human embryonic stem cells in biomedical research.
Following the successful passage of Proposal O8-02 in late 2008, the Consortium for Stem Cell Therapies was created as a stem cell derivation facility at U-M, and later renamed M Stem Cell Laboratories. The lab produced announced its first stem cell line in 2010.
Today, M Stem Cell is the leading academic institution in the United States in the production of disease-specific human embryonic stem cell (ds-hESC) lines and in submission and acceptance of lines to the National Institutes of Health (NIH). The laboratory operates with national and state oversight, and is in compliance with all reporting requirements.
Disease-specific lines are important to the in vitro study of genetic diseases because they allow researchers to test new therapies without risk to human patients.
As of late 2018, M Stem Cell has produced 32 separate disease-specific lines related to diseases such as hypertrophic cardiomyopathy and Fragile X syndrome.
M Stem Cell laboratories also performs a variety of outreach efforts, including:
- Training investigators and scientists throughout U-M in the use of stem cell lines
- Fostering collaboration among researchers in various disciplines at U-M
- Presentations to scientific and general audiences throughout the United States on the impact of stem cells in research
- Education about the donation of screened embryos to be used in the creation of additional stem cell lines
- Publication of numerous peer-reviewed papers in prestigious medical journals
To learn more about donating embryos, call our study coordinator at (734) 649-6557.